Skip to main content

Table 2 Costs, effects and incremental cost-effectiveness ratios (ICER) for the base case scenario. Data indicate mean values per infant

From: Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

 

Prophylaxis

No Prophylaxis

Difference

Prophylaxis

3664 EUR

0 EUR

3664 EUR

RSV-hospitalizations

5171 EUR

10,315 EUR

−5145 EUR

 General

499 EUR

691 EUR

− 191 EUR

 ICU

286 EUR

1279 EUR

− 993 EUR

 Supplemental oxygen

96 EUR

349 EUR

− 253 EUR

 Mechanical ventilation

23 EUR

188 EUR

− 165 EUR

 CPAP

400 EUR

727 EUR

− 327 EUR

 ECMO

3744 EUR

6806 EUR

− 3063 EUR

 Hotel nights

55 EUR

124 EUR

−69 EUR

 Productivity losses

68 EUR

152 EUR

−84 EUR

Heart complications

2544 EUR

4626 EUR

−2082 EUR

Asthma

1470 EUR

1739 EUR

− 270 EUR

Total costs

12,848 EUR

16,681 EUR

−3833 EUR

Total QALYs

17.82

17.75

0.06

Total LY

20.15

20.12

0.03

ICER (QALY)

  

DOMINANCE

ICER (LYG)

  

DOMINANCE

  1. CPAP Continuous positive airway pressure, ECMO Extracorporeal membrane oxygenation, ICER incremental cost-effectiveness ratio, ICU Intensive care unit, LY Life year, LYG Life year gained, Proph prophylactic, RSV Respiratory syncytial virus, QALY quality-adjusted life year, y years